Personalized Neoantigen Cancer Vaccine VB10.NEO

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A personalized cancer vaccine consisting of DNA plasmids encoding patient-specific neoantigens, which are immunogenic and unique to the patient's tumor, linked to an intrinsic adjuvant, a chemokine MIP-1alpha (CCL3; MIP-1a)-expressing, endocytic chemokine receptor-targeting unit, with potential immunomodulating and antineoplastic activities. Upon intramuscular administration of the personalized neoantigen cancer vaccine VB10.NEO, the patient-specific neoantigens are translated in cells and the translated proteins specifically and covalently bind to, with the targeting unit that expresses the natural ligand of endocytic chemokine receptor CCL3, to the endocytic receptors on antigen-presenting cells (APCs), thereby allowing efficient uptake and presentation of the neoantigens. Also, CCL3 attracts immune cells by chemotaxis and induces the maturation of APC locally. This elicits a specific and potent tumor antigen-specific cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these neoantigens, resulting in tumor cell lysis. MIP-1a attracts APCs and may therefore induce a stronger CD8 killer T-cell immune response against the tumor cells. VB10.NEO is able to hold up to at least forty neoepitopes.

**Synonyms:** - DNA Plasmid Vaccine VB10.NEO - DNA-based Neoantigen Vaccine VB10.NEO - Individualized Cancer Neoantigen Vaccine VB10.NEO - VB10 NEO - VB10-NEO - VB10.NEO - VB10NEO - Vaccine VB10.NEO